Skip to content

Esperion Therapeutics ESPR Weighted Average Exercise Price of Vested and Expected to Vest Options

Weighted Average Exercise Price of Vested and Expected to Vest Options at other companies

Organon logo
OrganonOGN
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$80.1M+23.2%
Operating income-$6.6M+70.2%
Net income-$25.2M+37.7%
EPS (diluted)-$0.10+52.4%

Balance sheet

See full
Cash & equivalents$156.2M+36.2%
Total debt$155.2M+6.1%
Total equity-$307.9M+27.8%
Total assets$462.5M+42.7%

Cash flow

See full
Operating cash flow-$27.7M-22.5%
CapEx$189.0K
Free cash flow-$27.9M-23.3%

Valuation

See full
Market cap$811.73M+283%
Enterprise value$810.81M+233%
P/S1.9×+1.1×

Profitability

See full
Operating margin18.1%+12.7pp
Net margin-34.8%+8.0pp
FCF margin-30.7%

Returns & leverage

See full
Return on equity-260.8%
Debt / equity0.8×
Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's weighted average exercise price of vested and expected to vest options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Esperion Therapeutics's weighted average exercise price of vested and expected to vest options?
Esperion Therapeutics (ESPR) reported weighted average exercise price of vested and expected to vest options of $5.06 in Q1 2026.
How has Esperion Therapeutics's weighted average exercise price of vested and expected to vest options changed year-over-year?
Esperion Therapeutics's weighted average exercise price of vested and expected to vest options decreased by 22.9% year-over-year, from $6.56 to $5.06.
What is the long-term trend for Esperion Therapeutics's weighted average exercise price of vested and expected to vest options?
Over 2 years (2020 to 2025), Esperion Therapeutics's weighted average exercise price of vested and expected to vest options has grown at a -62.0% compound annual growth rate (CAGR), from $40.24 to $5.81.
What does weighted average exercise price of vested and expected to vest options mean?
This represents the average price at which employees or directors can purchase company shares for options that are currently vested or expected to vest. It is a critical metric for evaluating the potential dilution of shareholder equity and the alignment of management incentives with stock performance. A higher exercise price generally indicates a higher threshold for value creation for option holders.